Nuclidium AG secured CHF79 million (approximately $99.3 million) in Series B funding to tackle production and supply bottlenecks in radiopharmaceuticals. The capital will support clinical development of copper isotope-based therapies and expansion of their global manufacturing network. This influx fortifies Nuclidium's position in radiopharma, addressing longstanding challenges in access and scalability within this specialized therapeutic sector.